Long-term risk of serious infections and mortality among patients surviving drug use-associated infective endocarditis.
Mary C FiggattDavid L RosenVivian H ChuLi-Tzy WuAsher J SchranzPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Among a statewide cohort of 1,874 patients surviving hospitalization for drug use-associated endocarditis during 2017-2020, the 3-year risk of death or future hospitalization was 38% (16% for death prior to later infection, 14% for recurrent endocarditis, 14% for soft-tissue, 9% for bacteremia, 5% for bone/joint, and 4% for spinal infections).